174 related articles for article (PubMed ID: 19737951)
41. Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy.
Kao CH; Lin SC; Hsieh TC; Yen KY; Yang SN; Wang YC; Liang JA; Hua CH; Chen SW
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1297-305. PubMed ID: 22532254
[TBL] [Abstract][Full Text] [Related]
42. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
Creaney J; Francis RJ; Dick IM; Musk AW; Robinson BW; Byrne MJ; Nowak AK
Clin Cancer Res; 2011 Mar; 17(5):1181-9. PubMed ID: 21177406
[TBL] [Abstract][Full Text] [Related]
43. Metabolic tumor volume of primary tumor predicts survival better than T classification in the larynx preservation approach.
Miyabe J; Hanamoto A; Tatsumi M; Hamasaki T; Takenaka Y; Nakahara S; Kishikawa T; Suzuki M; Takemoto N; Michiba T; Yoshioka Y; Isohashi F; Konishi K; Ogawa K; Hatazawa J; Inohara H
Cancer Sci; 2017 Oct; 108(10):2030-2038. PubMed ID: 28787757
[TBL] [Abstract][Full Text] [Related]
44. Correlation of pretreatment
Chen SW; Shen WC; Lin YC; Chen RY; Hsieh TC; Yen KY; Kao CH
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):567-580. PubMed ID: 27999896
[TBL] [Abstract][Full Text] [Related]
45. Pretreatment maximal standardized uptake value of the primary tumor predicts outcome to radiotherapy in patients with pharyngeal cancer.
Lin SC; Liao CY; Kao CH; Yen KY; Yang SN; Wang YC; Liang JA; Chen SW
J Radiat Res; 2012; 53(3):462-8. PubMed ID: 22739016
[TBL] [Abstract][Full Text] [Related]
46. Validation of metabolic tumor volume as a prognostic factor for oral cavity squamous cell carcinoma treated with primary surgery.
Zhang H; Seikaly H; Nguyen NT; Abele JT; Dziegielewski PT; Harris JR; O'Connell DA
Oral Oncol; 2016 Jun; 57():6-14. PubMed ID: 27208838
[TBL] [Abstract][Full Text] [Related]
47. Clinical outcomes of IMRT planned with or without PET/CT simulation for patients with pharyngeal cancers.
Matsuura T; Nishimura Y; Nakamatsu K; Kanamori S; Ishikawa K; Tachibana I; Hosono M; Shibata T
Int J Clin Oncol; 2017 Feb; 22(1):52-58. PubMed ID: 27604973
[TBL] [Abstract][Full Text] [Related]
48. Value of volume-based metabolic parameters for predicting survival in breast cancer patients treated with neoadjuvant chemotherapy.
Kim TH; Yoon JK; Kang DK; Kang SY; Jung YS; Han S; Kim JY; Yim H; An YS
Medicine (Baltimore); 2016 Oct; 95(41):e4605. PubMed ID: 27741099
[TBL] [Abstract][Full Text] [Related]
49. [Up-to-date methods of tomographic diagnostics for the evaluation of effectiveness of the treatment of laryngeal and laryngopharyngeal cancer].
Iudin AL; Vasil'ev PV; Pokrovskiĭ IuA
Vestn Otorinolaringol; 2010; (3):47-9. PubMed ID: 20559253
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of metabolic tumor volume in patients with piriform sinus carcinoma treated by radiotherapy with or without concurrent chemotherapy.
Yabuki K; Sano D; Shiono O; Arai Y; Takahashi H; Chiba Y; Tanabe T; Nishimura G; Takahashi M; Taguchi T; Kaneta T; Hata M; Oridate N
Head Neck; 2016 Nov; 38(11):1666-1671. PubMed ID: 27143103
[TBL] [Abstract][Full Text] [Related]
51. Concurrent chemo-radiotherapy potentiates vascular inflammation: increased FDG uptake in head and neck cancer patients.
Wang YC; Hsieh TC; Chen SW; Yen KY; Kao CH; Chang KC
JACC Cardiovasc Imaging; 2013 Apr; 6(4):512-4. PubMed ID: 23579012
[No Abstract] [Full Text] [Related]
52. 18 FDG-PET/CT: 21st century approach to leukemic tumors in 124 cases.
Cunningham I; Kohno B
Am J Hematol; 2016 Jun; 91(4):379-84. PubMed ID: 26718745
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma.
Oiwa K; Fujita K; Lee S; Morishita T; Tsujikawa T; Negoro E; Hara T; Tsurumi H; Ueda T; Yamauchi T
Ann Hematol; 2023 May; 102(5):1141-1148. PubMed ID: 36951966
[TBL] [Abstract][Full Text] [Related]
54. Retropharyngeal neuroblastoma in an infant: management without surgery.
Matsumura R; Ohta H; Kusuki S; Yoshida H; Sato E; Hashii Y; Uehara S; Oue T; Fukuzawa M; Ishida H; Ozono K
J Pediatr Hematol Oncol; 2010 May; 32(4):e160-3. PubMed ID: 20445413
[TBL] [Abstract][Full Text] [Related]
55. [The correlation between the rise of tumor temperature during hyperthermia treatment and tumor blood flow measured by dynamic CT and 15 O gas-positron emission tomography].
Hattori H
Nihon Igaku Hoshasen Gakkai Zasshi; 1993 Mar; 53(3):329-37. PubMed ID: 8474867
[TBL] [Abstract][Full Text] [Related]
56. Positive response to steroid therapy for autoimmune pancreatitis evaluated with fluorodeoxyglucose positron emission tomography.
Takuma K; Kamisawa T; Itoi T
Clin Gastroenterol Hepatol; 2010 May; 8(5):e54-5. PubMed ID: 20060066
[No Abstract] [Full Text] [Related]
57. [Radiological evaluation of tumor response in oncological studies (tumor response evaluation)].
Gebauer B; Bohnsack O; Riess H
Rofo; 2011 Aug; 183(8):695-703. PubMed ID: 21391174
[TBL] [Abstract][Full Text] [Related]
58. Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone.
Miller S; Li P; Schipper M; Junck L; Piert M; Lawrence TS; Tsien C; Cao Y; Kim MM
Adv Radiat Oncol; 2020; 5(1):53-61. PubMed ID: 32051890
[TBL] [Abstract][Full Text] [Related]
59. Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?
Im HJ; Bradshaw T; Solaiyappan M; Cho SY
Nucl Med Mol Imaging; 2018 Feb; 52(1):5-15. PubMed ID: 29391907
[TBL] [Abstract][Full Text] [Related]
60. Multi-level otsu method to define metabolic tumor volume in positron emission tomography.
Im HJ; Solaiyappan M; Lee I; Bradshaw T; Daw NC; Navid F; Shulkin BL; Cho SY
Am J Nucl Med Mol Imaging; 2018; 8(6):373-386. PubMed ID: 30697457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
